Giovanna Carpentieri

Giovanna Carpentieri

Auto-generated profile, based on publicly available information

Giovanna Carpentieri

Molecular Genetics and Functional Genomics, Ospedale Pediatrico Bambino Gesù, IRCCS, 00146 Rome, Italy; Department of Oncology and Molecular Medicine, Istituto Superiore di Sanità, 00161 Rome, Italy

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 August 2024 in Human Genetics and Genomics Advances
Verified
Journal Article
Open access
GCGiovanna Carpentieri
Giovanna Carpentieri
SCSerena Cecchetti
Serena Cecchetti
Gianfranco BocchinfusoGianfranco Bocchinfuso
Gianfranco Bocchinfuso
FRFrancesca Clementina Radio
Francesca Clementina Radio
CLchiara leoni
chiara leoni
EFElisabetta Flex
Elisabetta Flex
The vacuolar H+-ATPase (V-ATPase) is a functionally conserved multimeric complex localized at the membranes of many organelles where its proton-pumping action is required for proper lumen acidification. The V-ATPase complex is composed of several subunits, some of which have been linked to human disease. We and others previously reported pathogenic dominantly acting variants in ATP6V1B2, the gene encoding the V1B2 subunit, as underlying a clinically variable phenotypic spectrum including dominant deafness-onychodystrophy (DDOD) syndrome, Zimmermann-Laband syndrome (ZLS), and deafness, onychodystrophy, osteodystrophy, intellectual disability, and seizures (DOORS) syndrome. Here, we report on an individual with features fitting DOORS syndrome caused by dysregulated ATP6V1C1 function, expand the clinical features associated with ATP6V1B2 pathogenic variants, and provide evidence that these ATP6V1C1/ATP6V1B2 amino acid substitutions result in a gain-of-function mechanism upregulating V-ATPase function that drives increased lysosomal acidification. We demonstrate a disruptive effect of these ATP6V1B2/ATP6V1C1 variants on lysosomal morphology, localization, and function, resulting in a defective autophagic flux and accumulation of lysosomal substrates. We also show that the upregulated V-ATPase function affects cilium biogenesis, further documenting pleiotropy. This work identifies ATP6V1C1 as a new gene associated with a neurodevelopmental phenotype resembling DOORS syndrome, documents the occurrence of a phenotypic continuum between ZLS, and DDOD and DOORS syndromes, and classify these conditions as lysosomal disorders.

29 January 2022 in European Journal of Medical Genetics
Verified
Journal Article
Closed access
CLchiara leoni
chiara leoni
MMMiriam Massese
Miriam Massese
JGJacopo Gervasoni
Jacopo Gervasoni
APAniello Primiano
Aniello Primiano
VGValentina Giorgio
Valentina Giorgio
GZGiuseppe Zampino
Giuseppe Zampino

12 September 2021 in Genes
Verified
Journal Article
Open access
PDF file
EFElisabetta Flex
Elisabetta Flex
Valentina ImperatoreValentina Imperatore
Valentina Imperatore
GCGiovanna Carpentieri
Giovanna Carpentieri
ABAlessandro Bruselles
Alessandro Bruselles
ACAndrea Ciolfi
Andrea Ciolfi
PPPaolo Prontera
Paolo Prontera
In recent years, a rare form of autosomal recessive brachyolmia associated with amelogenesis imperfecta (AI) has been described as a novel nosologic entity. This disorder is characterized by skeletal dysplasia (e.g., platyspondyly, short trunk, scoliosis, broad ilia, elongated femoral necks with coxa valga) and severe enamel and dental anomalies. Pathogenic variants in the latent transforming growth factor-β binding protein 3 (LTBP3) gene have been found implicated in the pathogenesis of this disorder. So far, biallelic pathogenic LTBP3 variants have been identified in less than 10 families. We here report a young boy born from consanguineous parents with a complex phenotype including skeletal dysplasia associated with aortic stenosis, hypertrophic cardiomyopathy, hypodontia and amelogenesis imperfecta caused by a previously unreported homozygous LTBP3 splice site variant. We also compare the genotypes and phenotypes of patients reported to date. This work provides further evidence that brachyolmia with amelogenesis imperfecta is a distinct nosologic entity and that variations in LTBP3 are involved in its pathogenesis.

28 August 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
SBSara Bobone
Sara Bobone
LPLuca Pannone
Luca Pannone
BBBarbara Biondi
Barbara Biondi
MSMaja Solman
Maja Solman
EFElisabetta Flex
Elisabetta Flex
Lorenzo StellaLorenzo Stella
Lorenzo Stella
We developed a new class of inhibitors of protein-protein interactions of the SHP2 phosphatase, which is pivotal in multiple signaling pathways and a central target in the therapy of cancer and rare diseases. Currently available SHP2 inhibitors target the catalytic site or an allosteric pocket but lack specificity or are ineffective on disease-associated SHP2 mutants. Based on the consideration that pathogenic lesions cause signaling hyperactivation due to increased SHP2 association with cognate proteins, we developed peptide-based molecules with low nM affinity for the N-terminal Src homology domain of SHP2, good selectivity, stability to degradation and an affinity for pathogenic variants of SHP2 up to 20 times higher than for the wild-type protein. The best peptide reverted the effects of a pathogenic variant (D61G) in zebrafish embryos. Our results provide a novel route for SHP2-targeted therapies and a tool to investigate the role of protein-protein interactions in the function of SHP2.

22 July 2026 in Rare
Verified
Journal Article
Open access
SHSophia Hammer-Hansen
Sophia Hammer-Hansen
HCHelene Cederroth
Helene Cederroth
GCGiovanna Carpentieri
Giovanna Carpentieri
LVLisenka E.L.M. Vissers
Lisenka E.L.M. Vissers
MCMattia Carvetta
Mattia Carvetta
Zeynep TümerZeynep Tümer
Zeynep Tümer